Parsons Capital Management Inc. RI Has $8.85 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Parsons Capital Management Inc. RI lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 36.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 21,818 shares of the medical research company’s stock after selling 12,380 shares during the period. Parsons Capital Management Inc. RI’s holdings in Thermo Fisher Scientific were worth $8,846,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. CBIZ Investment Advisory Services LLC raised its holdings in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares during the period. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth about $30,000. Keystone Global Partners LLC acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth about $31,000. IMA Advisory Services Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth about $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth about $37,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of a number of analyst reports. William Blair initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an “outperform” rating on the stock. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. UBS Group upped their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. Evercore ISI reduced their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. Finally, HSBC reaffirmed a “hold” rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $583.53.

Thermo Fisher Scientific Stock Up 9.6%

TMO opened at $531.69 on Thursday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock has a market cap of $200.77 billion, a price-to-earnings ratio of 30.75, a PEG ratio of 2.63 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $616.57. The company’s 50-day moving average price is $480.27 and its two-hundred day moving average price is $447.56.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the company earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last three months. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.